News

STAT1h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Nature19h
Obesity drugs show promise treating a new ailment: migraine
Head-splitting migraines could be the next ailment in a seemingly endless list that a class of blockbuster weight-loss drugs ...
BioPharma Dive3h
Novo abruptly ends obesity drug deal with Hims
The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...
News-Medical.Net on MSN1h
New oral drug shows promise for type 2 diabetes and obesity without side effects
Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the ...
The New England Journal of Medicine6h
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
Obesity: Costs and impacts in Canada
On June 19, 2025 The Globe and Mail hosted an event where experts discussed how treating obesity as a chronic disease can ...
The New England Journal of Medicine19h
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Participants with obesity (obesity cohort) were randomly assigned in a 3:3:3:2:2:2:3 ratio to receive maridebart cafraglutide subcutaneously at a dose of 140, 280, or 420 mg every 4 weeks without ...